Patents by Inventor Donald P. McDonnell

Donald P. McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer using selective estrogen receptor modulators
    Patent number: 12263142
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: April 1, 2025
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20250090496
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 5, 2024
    Publication date: March 20, 2025
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20250064757
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 8, 2024
    Publication date: February 27, 2025
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20240366534
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: July 4, 2024
    Publication date: November 7, 2024
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20240197654
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: March 4, 2024
    Publication date: June 20, 2024
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Lasofoxifene treatment of breast cancer
    Patent number: 11980597
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 14, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Lasofoxifene treatment of breast cancer
    Patent number: 11974983
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: May 7, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Method of treating cancer using selective estrogen receptor modulators
    Patent number: 11951080
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: April 9, 2024
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20230398085
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: August 29, 2023
    Publication date: December 14, 2023
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Method of treating cancer using selective estrogen receptor modulators
    Patent number: 11779552
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: October 10, 2023
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P McDonnell
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20230233490
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: March 30, 2023
    Publication date: July 27, 2023
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20230157995
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: September 22, 2022
    Publication date: May 25, 2023
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20230131271
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: December 15, 2022
    Publication date: April 27, 2023
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Lasofoxifene treatment of breast cancer
    Patent number: 11497730
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 15, 2022
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20220110893
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P McDonnell
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20220031658
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 9, 2018
    Publication date: February 3, 2022
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20210361596
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 25, 2021
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Lasofoxifene treatment of breast cancer
    Patent number: 10905659
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: February 2, 2021
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200368184
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200121621
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell